Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.
心衰竭患者中 SGLT2 抑制伴隨的機制性蛋白質特徵的再確認:EMPEROR 計畫的驗證隊列。
J Am Coll Cardiol 2024-09-01
Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy.
SGLT2抑制劑在糖尿病心肌病中心血管益處的潛在機制:多組學觀點。
Front Cardiovasc Med 2022-10-25
Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.
將「Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria.」翻譯為繁體中文如下:「利用 SGLT2 抑制劑 empagliflozin 進行結構再利用,以增強抗心臟衰竭活性並降低糖尿病。」
Acta Pharm Sin B 2023-05-05
Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes.
多組學分析揭示 empagliflozin 在高葡萄糖處理的人類心肌細胞中減輕細胞壓力。
J Transl Med 2023-11-23
SGLT2 inhibition, plasma proteins, and heart failure: a proteome-wide Mendelian Randomization and colocalization study.
SGLT2 抑制、血漿蛋白和心臟衰竭:一項蛋白質組學的 Mendelian Randomization 和共定位研究。
Front Cardiovasc Med 2024-05-10
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
Empagliflozin 透過抑制 NHE1-NO 通路來預防心衰竭,與 SGLT2 無關。
Basic Res Cardiol 2024-07-24
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure.
Empagliflozin 對鐵代謝的影響作為改善非糖尿病收縮性心衰竭患者臨床結果的可能機制。
Nat Cardiovasc Res 2024-08-28
The effects of SGLT-2 inhibitors on echocardiographic indices and antioxidative properties in patients with heart failure with reduced ejection fraction and diabetes mellitus.
SGLT-2 抑制劑對於心臟射出分數降低及糖尿病患者的超聲心動圖指標和抗氧化特性的影響。
Eur Rev Med Pharmacol Sci 2024-09-04